Fig. 6: Mutation landscape of pre-treatment oral rinse-derived ctDNA. | npj Precision Oncology

Fig. 6: Mutation landscape of pre-treatment oral rinse-derived ctDNA.

From: Integrated analysis of oral rinse-derived and plasma circulating tumour DNA for mutation profiling and outcome prediction with oral squamous cell carcinoma

Fig. 6

A Overview of oral rinse-derived ctDNA status, clinical characteristics, and 1-year recurrence at baseline. B, C Kaplan–Meier estimates of PFS (B) and OS (C) according to pre-treatment oral rinse-derived ctDNA status. ctDNA circulating tumour DNA, PFS progression-free survival, OS overall survival.

Back to article page